Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by wildbird1on Dec 12, 2021 12:48pm
798 Views
Post# 34223069

Nothing short of miraculous....

Nothing short of miraculous....When TLT said" Comparing the 90 days and the 180 days assesment data, demonstrate that once a patients has obtained CR(Complete Response) or PR the duration of the response remain fairly durable".

Optimized Patients...
What the above mean is as we speak the potential CR(Complete Response) % is around 94.4 % at 90 days for the optimized patients. Knowing that the the CR % remain fairly durable, just to be on the safe side... TLT optimized patients could easily acheive 75 to 85% CR(Complete Response) at 180,260 ...days (that would be huge not to say humongous).

The big question is... Why is it that the optimized patients remain cancer free after 90,180,260...days????

To find a possible answer we have to go back to 2014 (TLT was doing preclinical studies).
PressRelease June 24,2014
PressRelease Nov  12, 2014
TLT said " TLT PDC technology demonstrates an ability to effectively destroy both Normoxix and Hypoxix cancer cells, this suggest an application of this technology to virtually all cancers, including later stage cancers(Bladder BCG resistant patients), that present with Hypoxix area and cores that can prove resistant to most form of treatment, also the ability of TLT PDC to destroy the original cancer and also program the body's immune system  to prevent its recurence, after only one single treatment, is nothing short of miraculous".

The above could be the reason for the durable response.

TLT treatment doesn't just cure the cancer...it can also program the immune system of the patient to fight recurrence on its own.

No wonder FDA gave fast-track designation to TLT.

How much money a big pharma Partner will be willing to pay, to be TLT partner in commercialization of this miraculous cancer treatment that could work virtually on all cancers.

All bets are open.




<< Previous
Bullboard Posts
Next >>